Status:
UNKNOWN
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
Lead Sponsor:
Assiut University
Conditions:
No-Reflow Phenomenon
Eligibility:
All Genders
Phase:
NA
Brief Summary
1- to find metabolic factors that correlate with the development of no reflow phenomenon that may help prevent its occurrence .
Detailed Description
Acute myocardial infarction (AMI) with its accompanying adverse sequelae is one of the most common causes of morbidity and mortality in the world . Although reperfusion techniques for ST- elevation m...
Eligibility Criteria
Inclusion
- diabetic patients with STEMI treated with primary PCI
Exclusion
- non diabetic . with selected PCI
- (1) a history of an unprotected left main artery with severe liver and kidney diseases or coronary artery bypass grafting .
- (2) patients who had valvular disease or cardiomyopathy . (3) severe dissection, thromboembolism in other parts, or vasospasm; and known malignancy .
- (4) patients with contraindications for anticoagulant therapy, such as active visceral hemorrhage, hemorrhagic stroke, or ischemic stroke within half a year (including transient ischemic attack), or aortic dissection, or patients with hematological diseases complicated with coagulation disorders .
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04835974
Start Date
May 1 2021
End Date
May 1 2022
Last Update
April 14 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.